Skip to main content

Table 1 Clinical characteristics of study subjects

From: Similar matrix alterations in alveolar and small airway walls of COPD patients

  Control GOLD II GOLD IV
Number 14 16 19
Age (years) 63 ± 6 65 ± 7 61 ± 7
Sex (M/F) 9/5 13/3 *$ 12/7
Pack-years § 25 ± 16 46 ± 14* 47 ± 29*
Smoking status (current/ex) 4/9 11/5 0/19*^
FEV 1 (%predicted) 107 ± 15 67 ± 9* 22 ± 4*^
FEV 1 /FVC 80 ± 6 59 ± 9* 26 ± 7*^
Tlco (% predicted) # 95 ± 16 77 ± 18* 35 ± 15*^
  1. Data are displayed as mean ± SD or ratio, * means p < 0.05 compared to controls, $ means significantly different compared GOLD IV. ^ means significant compared to GOLD II. § Values from 3 controls, 4 COPD GOLD II and 2 GOLD IV patients are missing. # Values from 2 controls, 1 COPD GOLD II and 9 GOLD IV patients are missing. FEV1 (%predicted) and FEV1/FVC are measured post-broncholdilation.